thymine has been researched along with Asthenia in 2 studies
Asthenia: Clinical sign or symptom manifested as debility, or lack or loss of strength and energy.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Trifluridine/tipiracil increases overall survival (OS) in patients with refractory, metastatic colorectal cancer (mCRC)." | 8.02 | Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data. ( Carmona-Bayonas, A; Carriles Fernández, C; Cousillas Castiñeiras, A; Covela Rúa, M; De la Cámara Gómez, J; Fernández Montes, A; Garcia García, T; Gonzalez Villarroel, P; Jimenez-Fonseca, P; Martinez Lago, N; Méndez, JCM; Sanchez Cánovas, M; Vázquez Rivera, F, 2021) |
| "Trifluridine/tipiracil increases overall survival (OS) in patients with refractory, metastatic colorectal cancer (mCRC)." | 4.02 | Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data. ( Carmona-Bayonas, A; Carriles Fernández, C; Cousillas Castiñeiras, A; Covela Rúa, M; De la Cámara Gómez, J; Fernández Montes, A; Garcia García, T; Gonzalez Villarroel, P; Jimenez-Fonseca, P; Martinez Lago, N; Méndez, JCM; Sanchez Cánovas, M; Vázquez Rivera, F, 2021) |
| "The purpose of the current study was to determine the maximum tolerated dose, dose-limiting toxicities, pharmacokinetic profile, and recommended Phase II dose of oral administration of TAS-102, a novel nucleoside formed by the combination of alpha,alpha,alpha-trifluorothymidine (FTD) and a thymidine phosphorylase inhibitor (TPI: 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidinedione)." | 2.72 | Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. ( Abbruzzese, JL; Bogaard, K; Fukushima, M; Hoff, PM; Hong, DS; Kuwata, K; Lassere, Y; Mita, A, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fernández Montes, A | 1 |
| Carmona-Bayonas, A | 1 |
| Jimenez-Fonseca, P | 1 |
| Vázquez Rivera, F | 1 |
| Martinez Lago, N | 1 |
| Covela Rúa, M | 1 |
| Cousillas Castiñeiras, A | 1 |
| Gonzalez Villarroel, P | 1 |
| De la Cámara Gómez, J | 1 |
| Méndez, JCM | 1 |
| Carriles Fernández, C | 1 |
| Sanchez Cánovas, M | 1 |
| Garcia García, T | 1 |
| Hong, DS | 1 |
| Abbruzzese, JL | 1 |
| Bogaard, K | 1 |
| Lassere, Y | 1 |
| Fukushima, M | 1 |
| Mita, A | 1 |
| Kuwata, K | 1 |
| Hoff, PM | 1 |
1 trial available for thymine and Asthenia
| Article | Year |
|---|---|
Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Area Under Curve; Asthenia; Dose-Response | 2006 |
1 other study available for thymine and Asthenia
| Article | Year |
|---|---|
Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Asthenia; Colorectal Neoplasms; Drug Combinations; Femal | 2021 |